Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Final Trades: Amgen, Exxon, Illinois Tool Works & more
03:05pm, Wednesday, 17'th Aug 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Has Moderna Made a Bear Market Blunder?
01:15pm, Wednesday, 17'th Aug 2022 The Motley Fool
The company has stood pat while other businesses have been busy with M&A.
The Zacks Analyst Blog Highlights Coca-Cola, Oracle, Morgan Stanley, Amgen and TotalEnergies
09:35am, Wednesday, 17'th Aug 2022 Zacks Investment Research
Coca-Cola, Oracle, Morgan Stanley, Amgen and TotalEnergies are included in this Analyst Blog.
Retail Scorecard and Analyst Reports for Coca-Cola, Oracle & Morgan Stanley
05:23pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Today's Research Daily features update on the Q2 earnings season and new research reports on The Coca-Cola Company (KO), Oracle (ORCL) and Morgan Stanley (MS).
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
01:40pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
11:17am, Tuesday, 16'th Aug 2022
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dividend Champion, Contender, And Challenger Highlights: Week Of August 14
04:50am, Sunday, 14'th Aug 2022 Seeking Alpha
Weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Check out the stocks with dividend changes and upcoming pay dates.
The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals
10:05am, Friday, 12'th Aug 2022 Zacks Investment Research
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates
03:25pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
01:39pm, Thursday, 11'th Aug 2022
The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on Thursday by the committee's chairman, Sena
Get ready for more merger mania in the pharma sector for the rest of the year
11:30am, Thursday, 11'th Aug 2022 MarketWatch
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.
Get ready for more merger mania in pharma sector the rest of the year
02:43pm, Tuesday, 09'th Aug 2022
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
11:30am, Tuesday, 09'th Aug 2022 Benzinga
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Needham lowered the price target
Two Appealing Biotech Stocks for Two Distinct investors
11:11am, Monday, 08'th Aug 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Amgen: Adding To The Pipeline
08:30am, Sunday, 07'th Aug 2022
Amgen has seen stagnation in recent years, as it has been pursuing M&A to bolster the pipeline and reignite growth. Deals still have to make a contribution, as stagnating sales, buybacks, deals and an
